EA201690456A1 - Способы лечения и предотвращения эндотелиальной дисфункции с применением бардоксолона метила или его аналогов - Google Patents

Способы лечения и предотвращения эндотелиальной дисфункции с применением бардоксолона метила или его аналогов

Info

Publication number
EA201690456A1
EA201690456A1 EA201690456A EA201690456A EA201690456A1 EA 201690456 A1 EA201690456 A1 EA 201690456A1 EA 201690456 A EA201690456 A EA 201690456A EA 201690456 A EA201690456 A EA 201690456A EA 201690456 A1 EA201690456 A1 EA 201690456A1
Authority
EA
Eurasian Patent Office
Prior art keywords
analogues
methods
methyl
bardoxolon
prevention
Prior art date
Application number
EA201690456A
Other languages
English (en)
Inventor
Мелани Пэй-Хэнг Чин
Колин Дж. Мейер
Original Assignee
Рита Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Рита Фармасьютикалз, Инк. filed Critical Рита Фармасьютикалз, Инк.
Publication of EA201690456A1 publication Critical patent/EA201690456A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Настоящее изобретение относится к способам лечения и предотвращения эндотелиальной дисфункции и родственных нарушений, в том числе, например, легочной артериальной гипертензии, с применением бардоксолона метила или его аналогов.
EA201690456A 2013-08-23 2014-08-22 Способы лечения и предотвращения эндотелиальной дисфункции с применением бардоксолона метила или его аналогов EA201690456A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361869527P 2013-08-23 2013-08-23
PCT/US2014/052382 WO2015027206A1 (en) 2013-08-23 2014-08-22 Methods of treating and preventing endothelial dysfunction using bardoxololone methyl or analogs thereof

Publications (1)

Publication Number Publication Date
EA201690456A1 true EA201690456A1 (ru) 2016-06-30

Family

ID=51794949

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690456A EA201690456A1 (ru) 2013-08-23 2014-08-22 Способы лечения и предотвращения эндотелиальной дисфункции с применением бардоксолона метила или его аналогов

Country Status (19)

Country Link
US (3) US20150080465A1 (ru)
EP (1) EP3035937A1 (ru)
JP (3) JP6564372B2 (ru)
KR (1) KR102322057B1 (ru)
CN (2) CN105517554B (ru)
AU (2) AU2014308600B2 (ru)
BR (1) BR112016003454B1 (ru)
CA (1) CA2921386A1 (ru)
CL (1) CL2016000405A1 (ru)
EA (1) EA201690456A1 (ru)
HK (1) HK1223015A1 (ru)
IL (3) IL285832B2 (ru)
MX (2) MX2016002375A (ru)
MY (1) MY198522A (ru)
NZ (4) NZ630951A (ru)
PH (1) PH12016500358A1 (ru)
SG (2) SG10201906113RA (ru)
TW (2) TWI716341B (ru)
WO (1) WO2015027206A1 (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201216958A (en) 2008-01-11 2012-05-01 Reata Pharmaceuticals Inc Synthetic triterpenoids and methods of use in the treatment of disease
TW201006474A (en) 2008-04-18 2010-02-16 Reata Pharmaceuticals Inc Natural products including an anti-flammatory pharmacore and methods of use
KR101735807B1 (ko) 2008-04-18 2017-05-15 리타 파마슈티컬스 잉크. Ｃ-17에 아미노 및 기타 변형을 갖는 올레아놀산 유도체를 포함하는 항산화 염증 조절제
US8513436B2 (en) 2010-12-17 2013-08-20 Reata Pharmaceuticals, Inc. Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
PL3444261T3 (pl) 2012-04-27 2021-07-19 Reata Pharmaceuticals, Inc. Pochodne 2,2-difluoropropionamidowe bardoksolonu metylu, ich kompozycje farmaceutyczne i formy polimorficzne do zastosowania w leczeniu określonych stanów
WO2013188818A1 (en) 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
WO2014040060A1 (en) 2012-09-10 2014-03-13 Reata Pharmaceuticals, Inc. C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof
WO2014040073A1 (en) 2012-09-10 2014-03-13 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
AR096046A1 (es) 2013-04-24 2015-12-02 Abbvie Inc Derivados de 2,2-difluoropropanamida de metil bardoxolona, formas polimórficas y métodos de uso
IL285832B2 (en) * 2013-08-23 2024-01-01 Reata Pharmaceuticals Inc Methods for the treatment and prevention of impaired functioning of the endothelium using brodoxolone methyl or its analogs
NZ734292A (en) 2015-02-12 2022-09-30 Reata Pharmaceuticals Inc Imidazolyl tricyclic enones as antioxidant inflammation modulators
AU2016326704B2 (en) 2015-09-23 2021-01-28 Reata Pharmaceuticals, Inc. C4-modified oleanolic acid derivatives for inhibition of IL-17 and other uses
CN110198718B (zh) 2016-11-08 2023-01-10 里亚塔医药控股有限责任公司 使用甲基巴多索隆或其类似物治疗阿尔波特综合征的方法
CN106632574B (zh) * 2016-12-07 2018-05-29 广东天键生物科技有限公司 一种化合物、其制备方法及用途
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
WO2018200692A1 (en) * 2017-04-26 2018-11-01 The Trustees Of The University Of Pennsylvania Methods and systems for virtual and augmented reality training for responding to emergency conditions
KR20210032936A (ko) 2018-06-15 2021-03-25 리아타 파마슈티컬즈, 아이엔씨. Il-17 및 ror감마의 저해를 위한 피라졸 및 이미다졸 화합물
EP3856755A4 (en) * 2018-09-28 2022-12-28 Sichuan Haisco Pharmaceutical Co., Ltd. TERPINOID DERIVATIVES AND THEIR USES
TW202028748A (zh) * 2018-10-17 2020-08-01 日商資生堂股份有限公司 檢定根據血液中之胱蛋白c含量之腎功能檢查結果之妥當性之方法
CN114729001A (zh) * 2019-11-27 2022-07-08 鲁南制药集团股份有限公司 一种齐墩果烷苯丙烯酰胺衍生物及其制备方法和用途
US11969424B2 (en) 2019-12-16 2024-04-30 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
CN115697319A (zh) * 2020-04-01 2023-02-03 四川海思科制药有限公司 三萜系化合物nrf2抑制剂的用途
US20230255982A1 (en) * 2020-05-09 2023-08-17 Reata Pharmaceuticals Holdings, LLC Methods of treating covid-19 using bardoxolone methyl or analogs thereof
CN111704647B (zh) * 2020-06-15 2021-10-22 中国人民解放军海军军医大学 一类三萜类衍生物及其作为程序性细胞坏死抑制剂的用途
AU2021397631A1 (en) 2020-12-11 2023-07-20 Reata Pharmaceuticals Holdings, LLC Synthetic triterpenoids for use in therapy
US20220401396A1 (en) * 2021-06-22 2022-12-22 Asklepion Pharmaceuticals, Llc Action of l-citrulline to prevent or treat endothelial dysfunction
CN114097807B (zh) * 2021-11-25 2023-05-05 兰州大学 巴多索隆类化合物在抗农业病原真菌中的用途
CN116509874A (zh) * 2023-02-01 2023-08-01 潍坊医学院附属医院 甲基巴多索隆在制备改善病毒性心肌炎或病毒性心肌损伤的药物中的用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
CA2072758A1 (en) 1990-09-14 1992-03-15 Kenneth Francis Buechler Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
CA2107899A1 (en) 1991-04-10 1992-10-11 Gunars Edwin Valkirs Novel conjugates and assays for simultaneous detection of multiple ligands
CA2107894C (en) 1991-04-10 2003-10-14 Kenneth F. Buechler Crosstalk inhibitors and their uses
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US6019944A (en) 1992-05-21 2000-02-01 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
GB9212302D0 (en) 1992-06-10 1992-07-22 Applied Research Systems Method for improving measurement precision in evanescent wave optical biosensor assays
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6025395A (en) 1994-04-15 2000-02-15 Duke University Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US7176237B2 (en) 2002-01-15 2007-02-13 The Trustees Of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
US20040102361A1 (en) * 2002-11-27 2004-05-27 Frederic Bodin Pharmaceutical composition for the treatment of pulmonary arterial hypertension
ZA200609228B (en) * 2004-04-23 2008-05-28 Celgene Corp Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension
US7714012B2 (en) 2006-11-17 2010-05-11 Trustees Of Dartmouth University Synthesis and biological activities of new tricyclic-bis-enones (TBEs)
JP5570415B2 (ja) 2007-05-08 2014-08-13 アボット・ラボラトリーズ 他のペプチド型に対する交差反応性の低いヒトｂ型ナトリウム利尿ペプチドアッセイ
US8088824B2 (en) 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
TW201216958A (en) 2008-01-11 2012-05-01 Reata Pharmaceuticals Inc Synthetic triterpenoids and methods of use in the treatment of disease
WO2009146216A2 (en) 2008-04-18 2009-12-03 Reata Pharmaceuticals. Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
KR101735807B1 (ko) 2008-04-18 2017-05-15 리타 파마슈티컬스 잉크. Ｃ-17에 아미노 및 기타 변형을 갖는 올레아놀산 유도체를 포함하는 항산화 염증 조절제
MX2010011437A (es) 2008-04-18 2010-12-20 Reata Pharmaceuticals Inc Moduladores antioxidantes de inflamacion: derivados del acido oleanolico con saturacion en el anillo c.
CA2721666C (en) 2008-04-18 2017-05-23 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives
TW201006474A (en) 2008-04-18 2010-02-16 Reata Pharmaceuticals Inc Natural products including an anti-flammatory pharmacore and methods of use
EP3254675B1 (en) 2009-02-13 2019-05-15 Reata Pharmaceuticals, Inc. Delayed release, oral dosage compositions that contain amorphous cddo-me
ME03713B (me) * 2010-04-12 2021-01-20 Reata Pharmaceuticals Inc Bardoksolon meтil za lečenje gojaznosтi
IL285832B2 (en) * 2013-08-23 2024-01-01 Reata Pharmaceuticals Inc Methods for the treatment and prevention of impaired functioning of the endothelium using brodoxolone methyl or its analogs
US20230255982A1 (en) * 2020-05-09 2023-08-17 Reata Pharmaceuticals Holdings, LLC Methods of treating covid-19 using bardoxolone methyl or analogs thereof

Also Published As

Publication number Publication date
TW202026003A (zh) 2020-07-16
IL285832B2 (en) 2024-01-01
NZ774222A (en) 2023-01-27
WO2015027206A1 (en) 2015-02-26
TWI717026B (zh) 2021-01-21
BR112016003454B1 (pt) 2023-02-14
JP6701407B2 (ja) 2020-05-27
JP6526306B2 (ja) 2019-06-05
HK1223015A1 (zh) 2017-07-21
IL244171B (en) 2020-02-27
IL244171A0 (en) 2016-04-21
CN112870202A (zh) 2021-06-01
MY198522A (en) 2023-09-04
IL272242A (en) 2020-02-27
JP6564372B2 (ja) 2019-08-21
SG10201906113RA (en) 2019-08-27
US20240115542A1 (en) 2024-04-11
CN105517554B (zh) 2021-01-15
US20190091194A1 (en) 2019-03-28
JP2016528300A (ja) 2016-09-15
AU2020203510B2 (en) 2023-05-11
IL272242B (en) 2021-09-30
NZ756256A (en) 2021-07-30
AU2020203510A1 (en) 2020-06-18
IL285832A (en) 2021-09-30
TWI716341B (zh) 2021-01-21
IL285832B1 (en) 2023-09-01
CL2016000405A1 (es) 2017-02-24
MX2016002375A (es) 2016-12-20
WO2015027206A8 (en) 2015-06-11
US20150080465A1 (en) 2015-03-19
MX2021002897A (es) 2021-06-08
AU2014308600B2 (en) 2020-03-05
CN105517554A (zh) 2016-04-20
KR102322057B1 (ko) 2021-11-05
KR20160061994A (ko) 2016-06-01
SG11201601202WA (en) 2016-03-30
JP2019048873A (ja) 2019-03-28
PH12016500358A1 (en) 2016-05-16
BR112016003454A2 (pt) 2017-08-01
AU2014308600A1 (en) 2016-03-03
EP3035937A1 (en) 2016-06-29
NZ744036A (en) 2020-09-25
TW201542211A (zh) 2015-11-16
JP2019131599A (ja) 2019-08-08
CA2921386A1 (en) 2015-02-26
NZ630951A (en) 2018-09-28

Similar Documents

Publication Publication Date Title
EA201690456A1 (ru) Способы лечения и предотвращения эндотелиальной дисфункции с применением бардоксолона метила или его аналогов
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
CY1121076T1 (el) Τρικυκλικες ενωσεις ως αντικαρκινικοι παραγοντες
EA201692316A1 (ru) Производные холана для применения при лечении и/или профилактике fxr и tgr5/gpbar1-опосредованных заболеваний
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
TR201901886T4 (tr) DNA-PK inhibitörleri.
EA201792536A1 (ru) Триазоловые агонисты рецептора apj
EA201791775A1 (ru) Цистеиновая протеаза
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
EA201890111A1 (ru) Замещенные производные оксопиридина
EA201891251A1 (ru) Бициклические ингибиторы pad4
EA201790266A1 (ru) Индолы для применения при инфекции, вызванной вирусом гриппа
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201692467A1 (ru) Вакцины против вируса гриппа и их применения
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
EA201692204A1 (ru) Композиции и способы модулирования экспрессии фактора комплемента b
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
EA201890810A1 (ru) Соединения, эффективные для лечения гепатотоксичности и стеатоза печени, и их применение
EA201690844A1 (ru) Ингибиторы gsk-3
EA201792604A1 (ru) Ингибиторы аутотаксина и их применения
EA202091865A1 (ru) Композиции и способы для снижения экспрессии tau
EA201690783A1 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
EA201792418A1 (ru) Применение cd24 для снижения уровней холестерина липопротеинов низкой плотности